Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

PHASE3CompletedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2008

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

pregabalin

pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period

DRUG

placebo

placebo + concurrent GAD treatment from the open-label study period

Trial Locations (68)

1083

Pfizer Investigational Site, Budapest

1137

Pfizer Investigational Site, Budapest

7623

Pfizer Investigational Site, Pécs

10614

Pfizer Investigational Site, Tallinn

11000

Pfizer Investigational Site, Belgrade

19004

Pfizer Investigational Site, Bala-Cynwyd

19063

Pfizer Investigational Site, Media

19136

Pfizer Investigational Site, Philadelphia

21208

Pfizer Investigational Site, Baltimore

29201

Pfizer Investigational Site, Columbia

32541

Pfizer Investigational Site, Destin

32547

Pfizer Investigational Site, Fort Walton Beach

33143

Pfizer Investigational Site, Miami

Pfizer Investigational Site, South Miami

34000

Pfizer Investigational Site, Kragujevac

38117

Pfizer Investigational Site, Memphis

38133

Pfizer Investigational Site, Memphis

38654

Pfizer Investigational Site, Olive Branch

44122

Pfizer Investigational Site, Beachwood

45227

Pfizer Investigational Site, Cincinnati

49005

Pfizer Investigational Site, Dnipropetrovsk

49115

Pfizer Investigational Site, Dnipropetrovsk

50417

Pfizer Investigational Site, Tartu

63301

Pfizer Investigational Site, Saint Charles

66212

Pfizer Investigational Site, Overland Park

67207

Pfizer Investigational Site, Wichita

68131

Pfizer Investigational Site, Omaha

70110

Pfizer Investigational Site, Kuopio

71024

Pfizer Investigational Site, Viljandi

71101

Pfizer Investigational Site, Shreveport

71104

Pfizer Investigational Site, Shreveport

77008

Pfizer Investigational Site, Houston

77074

Pfizer Investigational Site, Houston

77566

Pfizer Investigational Site, Lake Jackson

79021

Pfizer Investigational Site, Lviv

80100

Pfizer Investigational Site, Joensuu

83037

Pfizer Investigational Site, Donetsk

87102

Pfizer Investigational Site, Albuquerque

91045

Pfizer Investigational Site, Luhansk

91403

Pfizer Investigational Site, Sherman Oaks

91506

Pfizer Investigational Site, Burbank

92374

Pfizer Investigational Site, Redlands

115522

Pfizer Investigational Site, Moscow

119034

Pfizer Investigational Site, Moscow

123367

Pfizer Investigational Site, Moscow

190121

Pfizer Investigational Site, Saint Petersburg

191180

Pfizer Investigational Site, Saint Petersburg

192019

Pfizer Investigational Site, Saint Petersburg

214018

Pfizer Investigational Site, Smolensk

214019

Pfizer Investigational Site, Smolensk

91007-3462

Pfizer Investigational Site, Arcadia

06360

Pfizer Investigational Site, Norwich

02114

Pfizer Investigational Site, Boston

08021

Pfizer Investigational Site, Clementon

10128-1708

Pfizer Investigational Site, New York

44109-1998

Pfizer Investigational Site, Cleveland

19104-3309

Pfizer Investigational Site, Philadelphia

53188-1660

Pfizer Investigational Site, Waukesha

602 00

Pfizer Investigational Site, Brno

412 01

Pfizer Investigational Site, Litoměřice

120 00

Pfizer Investigational Site, Prague

158 00

Pfizer Investigational Site, Prague

163 00

Pfizer Investigational Site, Prague

181 03

Pfizer Investigational Site, Praha 8 - Bohnice

00029 HUS

Pfizer Investigational Site, Helsinki

11 000

Pfizer Investigational Site, Belgrade

Unknown

Pfizer Investigational Site, Belgrade

01030

Pfizer Investigational Site, Kyiv

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00413010 - Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD). | Biotech Hunter | Biotech Hunter